Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China

NCT03792529 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT03792529
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03792529 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prognosis and Targeted Therapy Related Molecular Screening Program for Patients of Breast Cancer in China
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Observational
Overall status
Unknown status
Start date
July 20, 2017
Completion date
June 1, 2019
Enrollment
300 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer